Biosimilars: A consideration of the regulations in the United States and European union.
about
Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.Drug tendering: drug supply and shortage implications for the uptake of biosimilarsRituximab biosimilar evaluated by network meta-analysis.Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
P2860
Biosimilars: A consideration of the regulations in the United States and European union.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Biosimilars: A consideration of the regulations in the United States and European union.
@en
type
label
Biosimilars: A consideration of the regulations in the United States and European union.
@en
prefLabel
Biosimilars: A consideration of the regulations in the United States and European union.
@en
P1476
Biosimilars: A consideration of the regulations in the United States and European union.
@en
P2093
Justin Daller
P304
P356
10.1016/J.YRTPH.2015.12.013
P407
P577
2015-12-27T00:00:00Z